Drug Trial Radar · NCT05271318
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
29
Planned (sponsor's estimate)
Start
May 17, 2022
Primary completion
Mar 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- TILT Biotherapeutics Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Mar 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, phase 1/1b, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.
Conditions
- Platinum-refractory Ovarian Carcinoma
- Platinum-resistant Ovarian Cancer
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Platinum-Refractory Fallopian Tube Carcinoma
- Platinum-Refractory Primary Peritoneal Carcinoma
- Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
- Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
- Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Interventions
TILT-123Biological
Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
pembrolizumabBiological
pembrolizumab, a monoclonal antibody binding PD-1
pegylated liposomal doxorubicinDrug
Pegylated Liposomal Doxorubicin is a chemotherapy and a pegylated liposomal form of the anthracycline topoisomerase inhibitor, doxorubicin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with any (serious and non-serious) Adverse EventsTime frame: Day 92
- Number of Participants with vital sign abnormalitiesTime frame: Day 92
- Number of Participants with abnormal laboratory valuesTime frame: Day 92
- Number of Participants with Adverse Events assessed by electrocardiograms (ECGs)Time frame: Day 92
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota
Northwell Heatlh/Lenox Hill Hospital
New York, New York
Docrates Cancer Center
Helsinki, Finland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.